Raj S Pruthi MD MHA, FACS
Minimally Invasive Surgery, Surgical Oncology
Professor and Chair of the University of California, San Francisco, Department of Urology
Join to View Full Profile
101 Manning DrChapel Hill, NC 27514
Phone+1 919-966-8596
Fax+1 919-843-5515
Dr. Pruthi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Raj Pruthi is a urologist in San Francisco, CA and is Professor and Chair at the University of California, San Francisco. He received his medical degree from Duke University School of Medicine and has been in practice 25 years. He specializes in urologic oncology and is experienced in prostate cancer, bladder cancer, minimally invasive surgery, and urologic oncology.
Education & Training
University of North CarolinaMHA, Masters of Health Administration , 2015 - 2017
Stanford Health Care-Sponsored Stanford UniversityResidency, Urology, 1992 - 1998
Duke University School of MedicineClass of 1992- Stanford UniversityBA, BS, Economics (BA), Biology (BS), 1984 - 1988
Certifications & Licensure
FL State Medical License 2023 - 2025
CA State Medical License 2019 - 2023
NC State Medical License 1998 - 2020
LA State Medical License 1999 - 2000
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification WebCIS, UNC Health Care, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy Start of enrollment: 2003 Apr 01
- Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2006 May 01
- A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy Start of enrollment: 2009 Mar 01
Publications & Presentations
PubMed
- 73 citationsTROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.Jonathan Chou, Kai Trepka, Martin Sjöström, Emily A Egusa, Carissa E Chu
European Urology Oncology. 2022-12-01 - 11 citationsVirtual "Matchmaking": Stakeholder Perspectives on the Future of the Urology Residency Match.Christopher J Warren, Chanan R Reitblat, Charles A Ferreri, Nicholas W Eyrich, Stephanie Daignault-Newton
Urology. 2022-06-01 - 108 citationsHeterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.Carissa Chu, Martin Sjöström, Emily A. Egusa, Ewan A. Gibb, Michelle L. Badura
Clinical Cancer Research. 2021-06-09
Press Mentions
Relmada (RLMD) Q3 2025 Earnings Call TranscriptNovember 13th, 2025- Perfect! OUWB Maintains 100% Success Rate in Urology with 2023 Early MatchFebruary 3rd, 2023
Health Tips This Experimental Prostate Cancer Treatment Is Shrinking TumorsApril 28th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
